Chow et al may explain the lack of correlation mentioned before and account in part for the synergistic affect of both drugs reported by our group. Nevertheless, the fact that we did not find a correlation between the CLB IC 50 in the presence of STI571 and the STI571 IC 50 is not in keeping with this hypothesis. Moreover, it has been shown that in CHO cells, proteolytic inactivation of Rad51 by a caspase-mediated mechanism contributes to the cell death response induced by IR-mediated DNA damage. 4 If this mechanism takes place in human B-lymphocytes, STI571 may decrease Rad51 related homologous recombinational repair (HRR) not only by decreasing c-abl-mediated Rad51 phosphorylation [5] [6] [7] and consequently HRR but also decreasing Rad51 protein levels. We summarize the possible pathways involved in STI571 and CLB-induced apoptosis in B-lymphocytes in Figure 1 We widely agree with Dr Aloyz' 1 interpretation and hypotheses arising from our complementary data 2 to her findings concerning the induction of synergistic effects on apoptosis in CLL lymphocytes by Imatinib and Chlorambucil.
We widely agree with Dr Aloyz' 1 interpretation and hypotheses arising from our complementary data 2 to her findings concerning the induction of synergistic effects on apoptosis in CLL lymphocytes by Imatinib and Chlorambucil. 3 However, we would like to offer some supplemental comments regarding the supposition of the function of Par-4 in Imatinib-induced apoptosis. Apart from being able to enhance caspase-3 activation under certain conditions, 4 Par-4 can be understood as a 'global sensitizing agent, whose functions/partners are modified in a context-specific manner' due to its interaction and interference with multiple apoptotic pathways, for example, WT-1, atypical PKCs, p62, DLK/ZIP kinase/Daxx, Bcl-2, FADD and DISC formation. 5 Owing to observations that Par-4 is depleted during apoptotic events induced by a variety of stimuli such as cytotoxic drugs, 6 Fas/TRAIL receptor agonists 7 or Imatinib, it is our hypothesis that high Par-4 levels act apoptosis sensitising by activating or enhancing context-specific apoptotic factors/pathways, and that Par-4 is thereby consumed in fulfilment of its function. This could explain why the tested CLL lymphocytes with high Par-4 expression were sensitive toward apoptosis by Imatinib alone as compared to cells that did not exhibit high Par-4 expression. The observations made in our experiments are not contradictory to Dr Aloyz' results, they rather show that high Par-4 expression may be a prerequisite for a further enhancement of the synergistic drug combination including Imatinib detected by Aloyz et al in CLL lymphocytes. 
